Evidence map›Paper›PMID 27278254›Full record

ArticleImmunology2016

Myeloid cell leukaemia 1 has a vital role in retinoic acid-mediated protection of Toll-like receptor 9-stimulated B cells from spontaneous and DNA damage-induced apoptosis.

Kristine L Holm, Randi L Indrevaer, June Helen Myklebust, Arne Kolstad, Jan Øivind Moskaug, Elin H Naderi, Heidi K Blomhoff

Open access · bronzeAbstract read
In one paragraph

Article in Immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kristine L HolmDepartment of Molecular Medicine, Institute of Basic Medical Science, University of Oslo, Oslo, Norway.
Randi L IndrevaerDepartment of Molecular Medicine, Institute of Basic Medical Science, University of Oslo, Oslo, Norway.
June Helen MyklebustDepartment of Immunology, Institute for Cancer Research, Oslo University Hospital HF, Montebello, Oslo, Norway.
Arne KolstadDepartment of Oncology, Division of Cancer Medicine, Surgery and Transplantation, Oslo University Hospital HF, Montebello, Oslo, Norway.
Jan Øivind MoskaugDepartment of Molecular Medicine, Institute of Basic Medical Science, University of Oslo, Oslo, Norway.
Elin H NaderiDepartment of Molecular Medicine, Institute of Basic Medical Science, University of Oslo, Oslo, Norway.
Heidi K BlomhoffDepartment of Molecular Medicine, Institute of Basic Medical Science, University of Oslo, Oslo, Norway.
University of Oslo · NONorwegian Cancer Society · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vitamin A is an essential anti-infective agent with pleiotropic effects on cells of the immune system. The goal of the present study was to unravel the impact of the vitamin A metabolite retinoic acid (RA) on B-cell survival related both to normal B-cell homeostasis and to the detrimental effects imposed by DNA-damaging agents. By combining RA with Toll-like receptor 9 (TLR9) ligands, we show that RA prevents spontaneous, irradiation- and doxorubicin-induced apoptosis of human B cells in an RA receptor-dependent manner. RA-mediated survival involved up-regulation of the anti-apoptotic protein myeloid cell leukemia 1 (MCL1) at the transcriptional level, and knock down of MCL1 by small interfering RNA partially reversed the effects of RA. To ensure that the combination of TLR9-ligands and RA would not promote the survival of malignant B cells, the combined effects of stimulation with RA and TLR9 ligands was assessed on cells from patients with B-cell malignancies. In contrast to the effects on normal B cells, the combination of TLR9 stimulation and RA neither enhanced the MCL1 levels nor inhibited the death of malignant B cells challenged by DNA-damaging agents. Taken together, the present results reveal a vital role of MCL1 in RA-mediated survival of normal B cells. Moreover, the findings suggest that RA in combination with TLR9 ligands might be useful adjuvants in the treatment of B-cell malignancies by selectively protecting normal and not malignant B cells from DNA-damage-induced cell death.

Indexed as

ApoptosisB-LymphocytesCell SurvivalDNA DamageDoxorubicinFemaleHomeostasisHumansLeukemia, B-CellLymphocyte ActivationMaleMiddle AgedNeoplasm StagingRadiationToll-Like Receptor 9TretinoinDoxorubicinToll-Like Receptor 9TretinoinVitamin AapoptosisB cellsmyeloid cell leukaemia 1retinoic acidToll like receptor 9

Identifiers

PMID27278254
PMCPMC4981614
OpenAlexW2417359391

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.